- Dallah Healthcare reported a profit of 155.6 million riyals in the first quarter of 2025.
- This represents a 30% increase compared to the same period last year, where the profit was 119.3 million riyals.
- The company’s revenue reached 832.8 million riyals, marking a 6.2% increase year-over-year.
- Operating profit for the quarter was recorded at 177.9 million riyals.
- Analyst ratings for the company include 2 buys, 7 holds, and 3 sells.
A look at Dallah Healthcare Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Dallah Healthcare Co has a promising long-term outlook. With a strong score in Growth and Resilience, the company seems well-positioned to expand and withstand market challenges. This indicates potential for Dallah Healthcare Co to continue its growth trajectory and adapt to changing market conditions.
Although Dallah Healthcare Co has average scores in Value, Dividend, and Momentum, its robust performance in Growth and Resilience suggests that the company’s strategic focus on expansion and operational strength could drive future success. As a provider of healthcare services in Saudi Arabia, Dallah Healthcare Co is positioned to capitalize on the growing demand for medical services in the region.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
